Germany-based health care company Fresenius Kabi has obtained approval from the US Food and Drug Administration to sell Naropin (ropivacaine HCL Injection, USP) 0.2% 100ml and 200ml premix bags in its Freeflex delivery system.
Freeflex bag has been designed for infusion solutions, which was marketed across the globe since 2005 and in the since 2008.
According to Fresenius, the bag’s multilayer polyolefin film is non-PVC and non-DEHP, which is developed for easy handling with enhanced safety and environmental performance in mind.
Fresenius Kabi USA president and CEO John Ducker said: "We introduced Naropin in Freeflex containers to give clinicians more choices and greater convenience in treating patients requiring continuous epidural infusions or local infiltration."
Naropin is also available in multiple presentations including single-dose vials, plastic ampule sterile-paks, and infusion bottles in four different strengths, in addition to the new 0.2% Freeflex bags.
Fresenius Kabi develops and markets medicines and technologies for infusion, transfusion and clinical nutrition.
The company provides ropivacaine portfolio for patient care in surgical anesthesia, labor and delivery, and acute pain management.
Image: Naropin for infusion is now available in the US in Fresenius Kabi’s Freeflex delivery system. Photo: courtesy of Business Wire.